Aytu BioScience, Inc. (NASDAQ: AYTU) today announced the Company's entry into the $3 billion cough and cold market with an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hedge Funds Management Comments

Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra(R) XRNovember 5, 2018 8:07 AM